Xcout Intel
Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Subscribe to see Regentis Biomaterials Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Regentis Biomaterials Ltd. at a glance
Regentis Biomaterials Ltd. is a biotech company headquartered in Herzliya, Israel, founded in 2004. It is publicly listed (RGNT) with a market capitalisation of $7.7M. Xcout tracks 14 named people at Regentis Biomaterials Ltd., including Ehud Geller (CEO & Executive Chairman).
Regentis Biomaterials Ltd. leadership
- Ehud GellerCEO & Executive Chairman
- Ori GonCFO & Chief Business Officer
- Arie GordashnikovChief Accounting Officer
- Galit ReskeChief Medical Officer
- Dror SeliktarCo-Founder & Chief Scientific Officer
- Arie GordashnikovExecutive Officer
8 more named people on record for Regentis Biomaterials Ltd., with roles, board committees and tenure — see the full roster →
Regentis Biomaterials Ltd. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $15M | 1 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Regentis Biomaterials Ltd. competitors
A few of Regentis Biomaterials Ltd.'s closest competitors — see the full list of competitors and alternatives →
CollPlant Biotechnologies Ltd. is a biotechnology company headquartered in Rehovot, Israel. The company focuses on regenerative medicine and reports its financial results in U.S. dollars.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Regenity Biosciences is a medical device supplier and biotechnology company headquartered in Paramus, New Jersey, specializing in regenerative medicine and collagen matrix products with nearly 30 years of history.
BLOOCELL is a biotechnology company specializing in artificial tissue technology, focusing on advanced bone and cartilage repair matrix solutions.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Get Regentis Biomaterials Ltd.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Regentis Biomaterials Ltd. in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access